blfs-20241231

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-K/A

Amendment No. 1

(Mark One)

☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the year ended December 31, 2024

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-36362

BioLife Solutions, Inc.

(Exact name of registrant as specified in its charter)


Delaware			94-3076866
(State or other jurisdiction of incorporation or organization)			(IRS Employer Identification No.)

3303 Monte Villa Parkway, Suite 310, Bothell, Washington, 98021

(Address of registrant’s principal executive offices, Zip Code)

(425) 402-1400

(Telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol	Name of exchange on which registered
Common stock, par value $0.001 per share	BLFS	The NASDAQ Stock Market, LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☑ No o

Indicate by check mark whether the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No ☑

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (S232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such said files). Yes ☑ No o


		Page No.
PART III

ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE	3
ITEM 11.	EXECUTIVE COMPENSATION	10
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	34
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE	36
ITEM 14.	PRINCIPAL ACCOUNTING FEES AND SERVICES	37

PART IV

ITEM 15.	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	37
	SIGNATURES	41


Name						Position with the Company
Roderick de Greef						Chief Executive Officer and Chairman of the Board
Troy Wichterman						Chief Financial Officer
Aby J. Mathew						Chief Scientific Officer and Executive Vice President
Todd Berard						Chief Marketing Officer
Garrie Richardson(1)						Former Chief Revenue Officer
Karen Foster						Chief Quality and Operations Officer


We Do						We Don’t
Pay for Performance: We emphasize market-based compensation that aligns the interests of our shareholders and executive officers through the use of both near-term cash incentive compensation and long-term equity awards subject to both time and market-based vesting.						Hedge or Pledge: We do not allow executive officers to engage in hedging or pledging of our securities.
Benchmark: We maintain an industry-specific peer group for annual benchmarking of executive compensation. This benchmarking is a key factor among those used to determine appropriate compensation for our NEOs.						Re-Pricing: We do not allow re-pricing of underwater stock options without shareholder approval.
Benefits: We offer market-competitive benefits for executives that are consistent with the benefits we offer all our employees.						Gross up Payments: We do not provide excise tax gross-up payments for our executive officers.
Consult: We consistently engage an independent compensation consultant to advise on compensation levels and practices.						Guaranteed Bonuses: We do not provide guaranteed bonuses to our executive officers.
Risk Assessment: We perform an annual compensation risk assessment.
Double Trigger: We provide each NEO severance benefits that are triggered only upon an involuntary termination of employment, including resignation for good reason, following a change-in-control (i.e., double trigger).


Name	2024 Base Salary ($) (1)	2023 Base Salary ($) (1)	Base Salary Increase in 2024 vs 2023 (%)
Roderick de Greef(2)	744,450	744,450	—
Aby J. Mathew	435,000	435,000	—
Troy Wichterman	472,000	472,000	—
Todd Berard(3)	370,000	332,000	11
Garrie Richardson(4)	367,500	367,500	—
Karen Foster	430,000	382,000	13


	Year Ended December 31,
	2024
GAAP Net loss from continuing operations	$	(11,387)

ADJUSTMENTS:
Interest expense, net	719
Accretion of available-for-sale investments	(476)
Income tax benefit	(38)
Depreciation	2,754
Intangible asset amortization	2,737
EBITDA	$	(5,691)

OTHER ADJUSTMENTS:
Share-based compensation (non-cash)	16,514
Acquisition and divestiture costs	1,260
Loss on disposal of assets	129
Change in fair value of investments	4,074
Other income	(979)
Inventory reserve costs	247
ADJUSTED EBITDA	$	15,554
% of Revenue	19		%


Name	Target Award as % of Salary for the Fiscal Year Ended December 31, 2024	Portion Tied to Company Objectives (%)
Roderick de Greef	100	100
Aby J. Mathew	45	100
Troy Wichterman	60	100
Todd Berard	50	100
Garrie Richardson	50	100
Karen Foster	45	100


Company Objectives for the Fiscal Year Ended December 31, 2024
Revenue target			Revenues of $82 million met maximum payout threshold of 39%
Adjusted EBITDA target			Adjusted EBITDA margin of 19% of total revenues met maximum payout threshold of 39%
Remediation of all material weaknesses			The Company remediated all material weaknesses from 2023. However, incurred one new material weakness in 2024, resulting in payout of 10%.
Implementation of NetSuite MRP module on Media			The Company did not fully implement the NetSuite MRP module on Media product line, resulting in 0% payout of this objective.


Name(1)	Target Award as % of Salary for the Fiscal Year Ended December 31, 2024	2024 Company Objectives Results (%)	2024 Bonus Payout ($)	2024 Overall Achievement % of Target Award
Roderick de Greef	100	88	655,116	88
Aby J. Mathew	45	88	172,260	40
Troy Wichterman	60	88	249,216	53
Todd Berard	50	88	148,004	44
Karen Foster	45	88	170,280	40


Name	Service-vesting based stock awards (#)	Target Market-based Stock Units (#)	Target Performance-based Stock Units (#)
Roderick de Greef(1)	—	109,512	109,512
Aby J. Mathew	25,470	25,470	—
Troy Wichterman	41,715	41,715	—
Todd Berard	14,456	14,456	—
Garrie Richardson(2)	12,516	25,032	—
Karen Foster	20,651	20,651	—


Name and Principal Positions (a)	Year (b)	Salary ($) (c)(1)		Bonus ($) (d)		Stock Awards ($) (e)(2)		Non-Equity Incentive Plan Compensation ($) (f)(3)		All Other Compensation ($) (g)		Total ($) (h)

Roderick de Greef	2024	744,450		—		5,571,874	(4)	655,116	(5)	74,765	(6)	7,046,205
Chief Executive Officer and	2023	198,890	(7)	62,740	(8)	4,588,883		—		466,285		5,316,798
Chairman of the Board	2022	450,000		—		1,747,823		185,850		—		2,383,673

Aby J. Mathew	2024	435,000		—		1,111,511	(9)	172,260	(10)	14,723	(11)	1,733,494
Executive Vice President and	2023	435,000		—		897,488		—		13,200		1,345,688
Chief Scientific Officer	2022	419,750		—		1,155,834		111,510		12,200		1,699,294

Troy Wichterman	2024	472,000		—		1,820,443	(12)	249,216	(13)	12,348	(14)	2,554,007
Chief Financial Officer	2023	472,000		—		1,212,021		—		13,200		1,697,221
	2022	375,000		—		1,245,968		121,688		12,200		1,754,856

Todd Berard - Chief Marketing Officer	2024	336,373	(15)	—		630,860	(16)	148,004	(17)	12,258	(18)	1,127,495

Garrie Richardson - Former Chief Revenue Officer	2024	317,479	(19)	—		651,833	(20)	—		417,976	(21)	1,387,288

Karen Foster	2024	430,000		—		901,210	(22)	170,280	(23)	13,649	(24)	1,515,139
Chief Quality and Operations	2023	382,000		—		727,677		—		13,200		1,122,877
Officer	2022	356,500		—		891,900		84,252		12,200		1,344,852


	Annual Retainer

Lead Director	$	40,000
Audit Committee Chair	$	13,750
Compensation Committee Chair	$	12,500
Governance and Nominating Committee Chair	$	10,000


Name	Annual Cash Retainer ($) (1)	Board and Committee Chair Fees ($)	Total Cash Compensation ($)
Amy DuRoss	60,000	52,500	112,500
Rachel Ellingson	60,000	—	60,000
Joydeep Goswami(2)	60,000	15,729	75,729
Tim Moore	60,000	—	60,000
Joseph Schick(2)	35,000	8,021	43,021


Name	Fees Earned or Paid in Cash ($)	Stock Awards ($) (1)(2)	Total Compensation ($)
Amy DuRoss	112,500	195,543	308,043
Rachel Ellingson	60,000	195,543	255,543
Joydeep Goswami	75,729	195,543	271,272
Tim Moore	60,000	195,543	255,543
Joseph Schick	43,021	195,543	238,564


Name						Number of Unvested RSUs (#)
Amy DuRoss						11,264
Rachel Ellingson						11,264
Joydeep Goswami						11,264
Tim Moore						11,264
Joseph Schick(1)						—


			Estimated Future Payouts Under Non-Equity Incentive Plan Awards			Estimated Future Payouts Under Equity Incentive Plan Awards			All Other Stock Awards: Number of	Grant Date Fair Value of
Name (a)	Award Type	Grant Date (b)	Threshold ($) (c)	Target ($) (d)	Maximum ($) (e)	Threshold (#) (c)	Target (#) (d)	Maximum (#) (e)	Shares of Stock or Units (#) (e)	Stock Awards ($) (f) (1)

Roderick de Greef	Cash incentive	-	148,890	744,450	878,451	—	—	—	—	—
Roderick de Greef	Performance-based RSUs(2)	3/8/2024				—	109,512	219,024	—	1,901,128
Roderick de Greef	Market-based RSUs	3/8/2024				—	109,512	219,024	—	2,877,975
Aby J. Mathew	Cash incentive	-	39,150	195,750	230,985	—	—	—	—	—
Aby J. Mathew	Market-based RSUs	3/8/2024				—	25,470	50,940	—	669,352
Aby J. Mathew	Service-vesting RSUs	3/8/2024				—	—	—	25,470	442,159
Troy Wichterman	Cash incentive	-	56,640	283,200	334,176	—	—	—	—	—
Troy Wichterman	Market-based RSUs	3/8/2024				—	41,715	83,430	—	1,096,270
Troy Wichterman	Service-vesting RSUs	3/8/2024				—	—	—	41,715	724,172
Todd Berard	Cash incentive	-	33,637	168,186	198,460	—	—	—	—	—
Todd Berard	Market-based RSUs	3/8/2024				—	14,456	28,912	—	379,904
Todd Berard	Service-vesting RSUs	3/8/2024				—	—	—	14,456	250,956
Garrie Richardson	Cash incentive	-	31,748	158,740	187,313	—	—	—	—	—
Garrie Richardson	Market-based RSUs(3)	3/8/2024				—	12,516	25,032	—	434,556
Garrie Richardson	Service-vesting RSUs	3/8/2024				—	—	—	12,516	217,278
Karen Foster	Cash incentive	-	38,700	193,500	228,330	—	—	—	—	—
Karen Foster	Market-based RSUs	3/8/2024				—	20,651	41,302	—	542,708
Karen Foster	Service-vesting RSUs	3/8/2024				—	—	—	20,651	358,501


	UNVESTED SHARES
Name (a)	Grant Date (b)	Number of shares or units of stock that have not vested (#) (c)		Market value of shares or units of stock that have not vested (1) ($) (d)	Equity incentive plan awards: Number of unearned shares, units or other rights that have not vested (#) (e)		Equity incentive plan awards: Market or payout value of unearned shares, units or other rights that have not vested ($)(1)(f)
Roderick de Greef	10/19/2023	296,142	(2)	7,687,846	—		—
Roderick de Greef	3/8/2024	—		—	219,024	(3)	5,685,863

Aby J. Mathew	2/8/2021	306	(4)	7,944	—		—
Aby J. Mathew	2/24/2022	6,572	(5)	170,609	—		—
Aby J. Mathew	1/3/2023	11,779	(6)	305,783	20,940	(7)	543,602
Aby J. Mathew	3/8/2024	25,470	(8)	661,201	25,470	(9)	661,201

Troy Wichterman	8/9/2021	355	(10)	9,216	—		—
Troy Wichterman	2/24/2022	7,302	(11)	189,560	—		—
Troy Wichterman	1/3/2023	19,292	(12)	500,820	34,296	(13)	890,324
Troy Wichterman	3/8/2024	41,715	(14)	1,082,921	41,715	(15)	1,082,921

Todd Berard	2/8/2021	226	(16)	5,867	—		—
Todd Berard	2/24/2022	4,381	(17)	113,731	—		—
Todd Berard	1/3/2023	6,686	(18)	173,569	11,885	(19)	308,535
Todd Berard	3/8/2024	14,456	(20)	375,278	14,456	(21)	375,278

Karen Foster	2/8/2021	260	(22)	6,750	—		—
Karen Foster	2/24/2022	5,112	(23)	132,708	—		—
Karen Foster	1/3/2023	9,551	(24)	247,944	16,978	(25)	440,749
Karen Foster	3/8/2024	20,651	(26)	536,100	20,651	(27)	536,100


	Option Awards		Stock Awards
Name (a)	Number of Shares Acquired on Exercise (#) (b)	Value Realized on Exercise ($) (c)(1)	Number of Shares Acquired on Vesting (#) (d)	Value Realized on Vesting ($) (e)(2)
Roderick de Greef	—	—	137,566	2,977,635
Aby J. Mathew	50,000	1,066,876	43,706	783,860
Troy Wichterman	—	—	54,134	970,911
Todd Berard	30,000	523,400	28,380	509,664
Garrie Richardson	—	—	123,868	2,919,942
Karen Foster	—	—	34,512	619,264


	Payments and Benefits
Name	Base Salary ($)	Accelerated Vesting of Equity Awards ($) (1)	Health Insurance Under COBRA ($)	Total ($)
Roderick de Greef	744,450	13,373,709	36,676	14,154,835
Aby J. Mathew	435,000	2,350,341	11,570	2,796,911
Troy Wichterman	472,000	3,755,763	22,714	4,250,477
Todd Berard	370,000	1,352,256	36,676	1,758,932
Karen Foster	430,000	1,900,350	25,491	2,355,841


	Payments and Benefits
Name	2024 Target Annual Cash Incentive ($)	Accelerated Vesting of Equity Awards ($) (2)	Total ($)
Roderick de Greef	655,116	13,373,709	14,028,825
Aby J Mathew	172,260	2,350,341	2,522,601
Troy Wichterman	249,216	3,755,763	4,004,979
Todd Berard	148,004	1,352,256	1,500,260
Karen Foster	170,280	1,900,350	2,070,630


Roderick de Greef (CEO) 2024 Compensation	$	7,046,205
Median Employee 2024 Compensation	$	122,390
CEO Pay Ratio	58:1


Name and Address of Beneficial Owner	Common Stock	Percentage of Class (1)
Directors and Executive Officers
Aby J. Mathew (Officer)(2)	287,957	*
Karen Foster (Officer)(3)	277,738	*
Roderick de Greef (Officer and Director)	231,651	*
Troy Wichterman(Officer)(4)	164,256	*
Todd Berard (Officer)(5)	126,187	*
Rachel Ellingson (Director)	49,825	*
Joydeep Goswami (Director)	47,986	*
Tim Moore (Director)	36,773	*
Amy DuRoss (Director)	30,687	*
Tony Hunt (Director)	6,876	*
Cathy Coste (Director)	5,701	*
Total shares owned by Executive Officers and Directors (13 persons)	1,343,259	2.8	%
5% Stockholders
Casdin Capital, LLC (6)	8,707,165	18.3	%
BlackRock, Inc.(7)	5,424,116	11.4	%
Invesco LTD (8)	3,242,364	6.8	%
The Vanguard Group (9)	2,571,608	5.4	%
Integrated Core Strategies (US) LLC (10)	2,404,862	5.1	%


Plan category	Number of securities to be issued upon exercise of outstanding options or rights (in thousands)	Weighted Average exercise price of outstanding options or rights		Number of granted restricted stock awards outstanding (in thousands)	Number of securities remaining available for future issuance under equity compensation plans (in thousands)
Equity compensation plans approved by stockholders: Second amended and restated 2013 performance incentive plan	127	$	2.67	478	1,070
Equity compensation plans approved by stockholders: 2023 Omnibus performance incentive plan	—	$	—	1,393	2,577


	2024		2023

Audit fees(1)	$	2,418,450	$	1,887,800
Audit related fees(2)	227,823		18,550
Total	$	2,646,273	$	1,906,350


Exhibit Number						Document
2.1†*						Agreement and Plan of Merger, dated as of March 19, 2021, by and among the Company, BLFS Merger Subsidiary, Inc., Global Cooling, Inc. and Albert Vierling and William Baumel, in their capacity as the representatives of the stockholders of Global Cooling, Inc. (included as Exhibit 2.1 to the current report on Form 8-K filed on March 25, 2021)
2.2†						Agreement and Plan of Merger, dated as of August 9, 2021, by and among the Company, BLFS Merger Sub, Inc., Sexton Biotechnologies, Inc. and Fortis Advisors LLC, in their capacity as the representatives of the stockholders of Sexton Biotechnologies, Inc. (incorporated by reference to Exhibit 2.6 to Company's report on Form 10-K filed March 31, 2022)
2.3***						Stock Purchase Agreement, dated April 17, 2024, by and between BioLife Solutions, Inc. and GCI Holdings Company, LLC (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed on April 23, 2024)


2.4***						Stock Purchase Agreement, dated November 12, 2024, by and between BioLife Solutions, Inc., SciSafe, Inc., and Subzero Purchaser Corp. (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed on November 12, 2024)
2.5***						Stock Purchase Agreement, dated November 14, 2024, by and between BioLife Solutions, Inc. and Standex International Corporation (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed on November 20, 2024)
3.1						Amended and Restated Certificate of Incorporation of BioLife Solutions, Inc. (included as Exhibit 4.1 to the Registration Statement on Form S-8 filed on June 24, 2013)
3.2						Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BioLife Solutions, Inc. (included as Exhibit 3.1 to the Current Report on Form 8-K filed on January 30, 2014)
3.3						Amended and Restated Bylaws of BioLife Solutions, Inc., effective November 12, 2024 (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed on November 12, 2024)
3.4						Certificate of Designations, Preferences, and Rights of Series A Preferred Stock (included as Exhibit 3.1 to the current report on Form 8-K filed on July 6, 2017)
4.1						Description of the Company’s Securities Registered under Section 12 of the Exchange Act (incorporated by reference to Exhibit 4.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)
10.1**						BioLife Solutions, Inc. 2023 Omnibus Incentive Plan (included as Exhibit 4.1 to the Registration Statement on Form S-8 for the fiscal year ended December 31, 2023 filed August 15, 2023)
10.2**						BioLife Solutions, Inc. Employee and Executive Form of Restricted Stock Unit Award Agreement pursuant to the 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's Annual Report on Form 10-K filed March 3, 2025)
10.3**						BioLife Solutions, Inc. Director Form of Restricted Stock Unit Award Agreement pursuant to the 2023 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company’s report on Form 10-K filed February 29, 2024)
10.4**						Second Amended and Restated 2013 Performance Incentive Plan (included as Appendix A to the Registrant’s Definitive Proxy Statement filed on April 14, 2017)
10.5**						Amendment No. 1 to Second Amended and Restated 2013 Performance Incentive Plan (included as Exhibit 10.2 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed March 31, 2021)
10.6**						BioLife Solutions, Inc. Form of Non-Plan Stock Option Agreement (included as Exhibit 4.4 to the Registration Statement on Form S-8 filed on June 24, 2013)
10.7**						Form of Restricted Stock Purchase Agreement pursuant to the Second Amended & Restated 2013 Performance Incentive Plan (included as Exhibit 10.4 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 filed on May 16, 2016)
10.8**						Form of Stock Option Agreement pursuant to the Second Amended & Restated 2013 Performance Incentive Plan (included as Exhibit 10.5 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 filed on May 16, 2016)
10.9**						Amendment No. 2 to BioLife Solutions, Inc. Second Amended and Restated 2013 Performance Incentive Plan (incorporated by reference to Exhibit 4.5 of the Registrant’s Registration Statement on Form S-8 filed on July 7, 2021)
10.10**						Amendment No. 3 to BioLife Solutions, Inc. Second Amended and Restated 2013 Performance Incentive Plan (incorporated by reference to Exhibit 4.6 of the Registrant's Registration Statement on Form S-8 filed on September 12, 2022)
10.11						Twelfth Amendment to the Lease, dated June 5, 2024, by and between the Company and ARE-SEATTLE No. 38, LLC (incorporated by reference to Exhibit 10 .1 1 to the Company's Annual Report on Form 10-K filed March 3, 2025 )
10.12						Lease Agreement dated October 1, 2019 for facility space 1102 Indiana Avenue, Indianapolis, IN 46202 (incorporated by reference to Exhibit 10.26 to Company's report on Form 10-K filed March 31, 2022)
10.13						Second Amendment to the Lease, dated November 5, 2024 for facility space 1102 Indiana Avenue, Indianapolis, IN 46202 (incorporated by reference to Exhibit 10.1 3 to the Company's Annual Report on Form 10-K filed March 3, 2025 )
10.14						Lease Agreement dated September 13, 2022 for facility space 19510 144th Avenue NE, Suite A-1, Woodinville, WA 98072 (incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K filed March 3, 2025 )
10.15*						Loan and Security Agreement, dated September 20, 2022, between BioLife Solutions, Inc. and Silicon Valley Bank (incorporated by reference to Exhibit 10.1 to the Company's report on Form 10-Q filed November 9, 2022)


10.16*						Waiver and First Amendment to Loan and Security Agreement, dated February 26, 2024, between BioLife Solutions, Inc. and First Citizens Bank and Trust Company (incorporated by reference to Exhibit 10.21 to the Company's Annual Report on Form 10-K filed February 29, 2024)
10.17						Consent and Second Amendment to Loan and Security Agreement, dated April 17, 2024, by and among Silicon Valley Bank, BioLife Solutions, Inc., SAVSU Technologies, Inc., Arctic Solutions, Inc., SciSafe Holdings, Inc., Global Cooling, Inc., and Sexton Biotechnologies, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed on April 23, 2024)
10.18						Consent and Third Amendment to Loan and Security Agreement, dated November 11, 2024, by and among Silicon Valley Bank, BioLife Solutions, Inc., SAVSU Technologies, Inc., Arctic Solutions, Inc., SciSafe Holdings, Inc., and Sexton Biotechnologies, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed on November 12, 2024)
10.19**						Executive Employment Agreement, dated October 19, 2023, by and between the Company and Roderick de Greef (incorporated by reference to Exhibit 10.2 to the Company’s report on Form 8-K filed October 23, 2023)
10.20**						Separation, Release of Claims and Consulting Agreement, dated October 19, 2023, by and between the Company and Michael Rice (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed October 23, 2023)
10.21**						Amended Employment Agreement dated January 5, 2023 between the Company and Aby Mathew (incorporated by reference to Exhibit 10.21 to the Company's Annual Report on Form 10-K filed March 3, 2025)
10.22**						Amended Employment Agreement dated June 1, 2023 between the Company and Todd Berard (incorporated by reference to Exhibit 10.22 to the Company's Annual Report on Form 10-K filed March 3, 2025)
10.23**						Amended Employment Agreement dated June 1, 2023 between the Company and Karen Foster (incorporated by reference to Exhibit 10.23 to the Company's Annual Report on Form 10-K filed March 3, 2025)
10.24**						Amended Employment Agreement dated June 1, 2023 between the Company and Sarah Aebersold (incorporated by reference to Exhibit 10.24 to the Company's Annual Report on Form 10-K filed March 3, 2025)
10.25**						Amended Employment Agreement dated June 1, 2023 between the Company and Troy Wichterman (incorporated by reference to Exhibit 10.25 to the Company's Annual Report on Form 10-K filed March 3, 2025)
10.26**						Board of Directors Services Agreement entered into May 4, 2015 by and between the Company and Other Non-Employee Directors (included as Exhibit 10.3 to the Current Report on Form 8-K filed on May 5, 2015)
10.27**						Form of Amendment to Employment Terms (incorporated by reference to Exhibit 10.1 to the Company’s report on Form 8-K filed August 16, 2023)
19.1						Insider Trading Policy (incorporated by reference to Exhibit 19.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)
21.1						List of the Company’s Subsidiaries (incorporated by reference to Exhibit 21.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)
23.1						Consent of Grant Thornton USA, LLP (incorporated by reference to Exhibit 23.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)
31.1						Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 31.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)
31.2						Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 31.2 to the Company's Annual Report on Form 10-K filed March 3, 2025)
31.3						Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
31.4						Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.1						Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 32.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)
32.2						Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated by reference to Exhibit 32.2 to the Company's Annual Report on Form 10-K filed March 3, 2025)
97.1						BioLife Solutions, Inc. Incentive-based compensation recovery policy (incorporated by reference to Exhibit 97.1 to the Company's Annual Report on Form 10-K filed March 3, 2025)
101.INS						Inline XBRL Instance Document (filed herewith)
101.SCH						Inline XBRL Taxonomy Extension Schema (filed herewith)


101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase (filed herewith)
101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase (filed herewith)
101.LAB						Inline XBRL Taxonomy Extension Label Linkbase (filed herewith)
101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase (filed herewith)
104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)


*			Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K. A copy of the omitted portions will be furnished supplementally to the Securities and Exchange Commission upon request.
**			Management contract or compensatory plan or arrangement.
***			Certain potions portions of this exhibit have been redacted pursuant to Item 601(a)(5) of Regulation S-K. A copy of the omitted portions will be furnished supplementally to the Securities and Exchange Commission upon request.
†			The exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.


Date:	April 8, 2025	BIOLIFE SOLUTIONS, INC.

		/s/ RODERICK DE GREEF
		Roderick de Greef
		Chief Executive Officer (principal executive officer) and Chairman of the Board of Directors

Amendment: SEC Form 10-K/A filed by BioLife Solutions Inc.